High-throughput saliva COVID-19 antibody test

2019年新型冠状病毒（SARS-CoV 2）可导致严重急性呼吸道综合征，也称为COVID-19。根据最近的报告，大多数COVID-19患者有轻微的流感样症状，然而，一小部分感染者迅速发展为急性呼吸窘迫综合征（ARDS）、感染性休克和其他并发症，有时会导致死亡。就新型冠状病毒感染及其控制措施所造成的死亡人数及经济影响而言，中国是受影响最严重的国家之一。英国政府与世界上许多其他卫生当局一样，已采取严厉的社交距离措施，作为防止疾病传播的主要策略。根据世界卫生组织（W.H.O.），需要采取快速诊断和立即隔离病例等综合措施来阻止病毒的传播。然而，由于需求不断增长，即使是那些有临床症状的人也往往无法进行测试。在疫苗问世之前，防止新冠肺炎快速传播的唯一方法是进行大规模检测，不仅要检测活动性感染者，还要检测已从感染中康复的人。目前的检测方法依赖于使用RT-qPCR检测病毒遗传物质。这些测试通常是相当可靠的，但是，他们需要从不愉快的鼻咽拭子获得的样本。拭子通常会错过病毒，因为它可能存在于患者体内的非常低的量（在早期感染或从感染中恢复后的情况下），或者它可能只是存在于拭子无法到达的喉咙的不同区域。这可能导致假阴性结果。检测新冠肺炎的另一种可靠方法是测量个体对感染的反应产生的抗体。这种检测也可以用于那些从感染中恢复的人。虽然此类检测通常使用血液进行，但Vidya的创新技术可以可靠准确地检测血液以外样本中的新冠病毒抗体。测试要求用户收集他们的样本（非侵入性）在一个小瓶发送给他们通过邮政返回到维迪亚的中心测试实验室也通过邮政。Vidya的超灵敏、高通量技术可以在收到样品后24小时内为用户提供结果。

The 2019-novel Corona virus (SARS-CoV2) can cause Severe Acute Respiratory Syndrome also called COVID-19. According to recent reports, most COVID-19 patients have mild flu like symptoms, however, a fraction of those infected rapidly progress to acute respiratory distress syndrome (ARDS), septic shock and further complications sometimes leading to death.The U.K. is one of the worst hit countries in terms of the death toll and the economic impact arising from Covid-19 infections and its control measures. The U.K. government like many other health authorities in the world have put in place drastic social distancing measures as their main strategy to avoid the spread of the disease. According to World Health Organization (W.H.O.), a combination of measures such as rapid diagnosis and immediate isolation of cases are needed to stop the spread of the virus. However, often even those with clinical symptoms aren't able to get a test due to the growing demand. Until a vaccine becomes available the only way to prevent the rapid spread of Covid-19 will be by mass testing, not only to detect those with active infections but also those who have recovered from the infection.The current testing approach relies on detection of the viral genetic material using RT-qPCR. These tests are generally quite reliable, however, they need samples obtained from unpleasant nasopharyngeal swabs. Swabs can often miss the virus as it could either be present in very low amounts in a patient (in cases of early infection or after recovery from infection) or it could just be present in a different area of the throat where the swab couldn't reach. This can lead to false-negative results. An alternative and reliable way of detecting Covid-19 is by measuring the antibodies produced by the individual in response to the infection. This detection can also work for those who have recovered from the infection. While such tests are often done using blood, Vidya's innovative technology can reliably and accurately detect antibodies against Covid-19 in samples other than blood. The tests requires the user to collect their sample (non-invasively) in a vial sent to them by post to be returned to Vidya's central testing lab also via post. Vidya's ultrasensitive, high-throughput technology can provide the user with their results within 24 hours of sample reception.